- Home
- RDI vs CNTX Comparison
RDI vs CNTX Comparison
Compare RDI & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDI | CNTX |
|---|---|---|
| Founded | 1937 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 47.7M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RDI | CNTX |
|---|---|---|
| Price | $1.73 | $0.19 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $4.14 |
| AVG Volume (30 Days) | 22.1K | ★ 1.1M |
| Earning Date | 11-17-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.76 | 17.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $202,988,000.00 | N/A |
| Revenue This Year | $15.10 | N/A |
| Revenue Next Year | $4.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.94 | $0.19 |
| 52 Week High | $2.41 | $3.62 |
Technical Indicators
Market Signals| Indicator | RDI | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.13 | 31.12 |
| Support Level | $1.69 | N/A |
| Resistance Level | $2.13 | $0.36 |
| Average True Range (ATR) | 0.12 | 0.02 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 48.09 | 21.12 |
Price Performance
Historical ComparisonAbout RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.